ProQR Therapeutics (PRQR) Equity Average (2022 - 2025)

ProQR Therapeutics' Equity Average history spans 3 years, with the latest figure at $69.6 million for Q4 2024.

  • For Q4 2024, Equity Average rose 23.63% year-over-year to $69.6 million; the TTM value through Dec 2024 reached $69.6 million, up 23.63%, while the annual FY2024 figure was $70.3 million, 22.23% up from the prior year.
  • Equity Average for Q4 2024 was $69.6 million at ProQR Therapeutics, up from $56.3 million in the prior quarter.
  • Across five years, Equity Average topped out at $99.3 million in Q4 2022 and bottomed at $56.3 million in Q4 2023.
  • The 3-year median for Equity Average is $69.6 million (2024), against an average of $75.1 million.
  • The largest annual shift saw Equity Average crashed 43.31% in 2023 before it grew 23.63% in 2024.
  • A 3-year view of Equity Average shows it stood at $99.3 million in 2022, then plummeted by 43.31% to $56.3 million in 2023, then rose by 23.63% to $69.6 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Equity Average are $69.6 million (Q4 2024), $56.3 million (Q4 2023), and $99.3 million (Q4 2022).